Brentuximab (SGN-35) in Transplant-Eligible Patients with Relapsed or Refractory Hodgkin Lymphoma

Protocol
11-142
Full Title
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase
II
Disease Status
Relapsed/Refractory
Purpose

The standard treatment for patients with Hodgkin lymphoma that has returned or stopped responding to therapy is chemotherapy with ICE (the drugs ifosfamide, carboplatin, and etoposide), followed by high-dose chemotherapy and radiation therapy and then an infusion of a patient’s own stem cells (autologous stem cell transplant, or ASCT). However, ICE can cause many side effects.

In this study, researchers are evaluating the use of the investigational drug brentuximab vedotin (also called SGN-35) instead of ICE before ASCT in patients with relapsed/refractory Hodgkin lymphoma. Brentuximab has two parts: one (an antibody) that attaches to a protein on the surface of cancer cells called CD30, and another (an anticancer drug called monomethyl auristatin E) that kills the cancer. Brentuximab has fewer side effects than ICE and can be given on an outpatient basis.

Each patient’s response to treatment will be monitored using positron emission tomography (PET) scanning.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have CD30-positive Hodgkin lymphoma that has stopped responding to or returned despite one prior regimen of therapy.
  • Patients infected with HIV or hepatitis B may not participate.
  • Patients must be between the ages of 12 and 72.

For more information about this study and to inquire about eligibility, please contact Dr. Alison Moskowitz at 212-639-4839.

Disease(s)
Lymphoma
Lymphoma: Hodgkin's Disease
Locations
Related Diseases